Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 2.

Journal Article

Gadea, O. Saavedra Santa, Greil, R., De Jonge, M. J. A., Tan, D., Jerusalem, G., Damian, S., Grell, P., Wainberg, Z., Wolf, J., Joerger, M., Carlino, M. S., Kasper, S., Yap, T. A., Otero, J., Yang, X., Nesbitt, V., Kim, J., Lee, L. Ho, Choudhury, S. and Leal, T. A. (2021). Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with microsatellite stable (MSS) colorectal cancer (CRC). Ann. Oncol., 32. S. S552 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Lin, C. C., Joerger, M., Grell, P., Chiappori, A. A., Leal, T. A., Kasper, S., Jerusalem, G., Goncalves, A., Wolf, J., De Braud, F., de Jonge, M. J. A., Otero, J., Chhagan, S., Cipolletta, D., Morris, E., Chowdhury, N. R., Hurtado, F. K. and Tan, D. S. (2020). Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients ( pts) with non-small cell lung cancer (NSCLC). Eur. J. Cancer, 138. S. S12 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

This list was generated on Thu Mar 28 14:36:28 2024 CET.